MedeliX
Start asking

Etoposide

Etoposid Accord, Etoposid Ebewe, Etoposid Hikma, Vepesid · ATC code L01CB01

Also known as: Etoposid · Brand names: Etoposid Accord, Etoposid Ebewe, Etoposid Hikma, Vepesid, Eto-Cell, Eto-Cell®, Eto-Gry, Etopophos, Etoposid Hexal, Riboposid, Vepesid K, Etopex, Etosid, Lastet, Oncopozid

Key facts
Active substance
Etoposide
ATC code
L01CB01
Authorisation
authorised nationally; no central EU authorisation
Information as of
2026-10-29

Boxed warning

WARNINGS

Etoposide should be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents. Severe myelosuppression with resulting infection or bleeding may occur.

Key facts

Etoposide is a cytotoxic anticancer drug (a podophyllotoxin derivative), here as oral capsules. Per the US prescribing information, it is used in combination with other chemotherapy as first-line treatment of small cell lung cancer.

What it is used for

  • Small cell lung cancer, first-line, in combination with other approved chemotherapeutic agents

Dosing

  • Oral dose is two times the IV dose rounded to the nearest 50 mg, i.e. two times 35 mg/m²/day for 4 days to 50 mg/m²/day for 5 days
  • Dose should be modified for the myelosuppressive effects of other drugs in the combination or of prior radiotherapy or chemotherapy
  • Renal impairment: creatinine clearance 15 to 50 mL/min – 75% of the dose initially; for creatinine clearance < 15 mL/min, further dose reduction should be considered
  • Capsules are stored refrigerated at 2° to 8°C

Contraindications

  • Previous hypersensitivity to etoposide or any component of the formulation

Important warnings

  • Boxed warning: to be given under the supervision of a physician experienced in cancer chemotherapy; severe myelosuppression with infection or bleeding may occur
  • Blood counts (platelets, hemoglobin, white cells and differential) before therapy and before each cycle; withhold therapy if platelets fall below 50,000/mm³ or neutrophils below 500/mm³
  • Acute leukemia has been reported rarely
  • Can cause fetal harm
  • Anaphylactic-like reactions

Side effects

  • Leukopenia (less than 4,000 WBC/mm³) in 60 to 91% and thrombocytopenia (less than 100,000 platelets/mm³) in 22 to 41%
  • Nausea and vomiting (31 to 43%), anorexia, diarrhea, mucositis
  • Reversible alopecia in up to 66% of patients, sometimes progressing to total baldness
  • Hypotension, allergic reactions, peripheral neurotoxicity

Interactions

  • Other myelosuppressive drugs in the combination: dose modification needed

Pregnancy and breastfeeding

  • Can cause fetal harm; teratogenic in mice and rats
  • Breastfeeding or the drug should be discontinued, depending on the importance of the drug to the mother

Summary of the official product information, written with AI on 2026-10-29. Every number was checked automatically against the original text. Not reviewed by a physician – the full official text is authoritative.

Full official text →

Common questions – ask Medelix

For patients

Patient information (US)

This product has no separate US patient information.

Authorisation and brand names by country

Medicines with exactly this active-substance composition, as listed in the national registers – alphabetical and without ranking. Whether a product is currently available is not shown here.

Austria

  • Etoposid AccordAccord Healthcare B.V. · 1 register entry
  • Etoposid EbeweEbewe Pharma · 1 register entry
  • Etoposid HikmaHikma Farmacêutica (Portugal), S.A. · 1 register entry
  • VepesidCheplapharm Arzneimittel Gmbh · 1 register entry

Source: EMA – Article 57 product data (EU/EEA), as of 2026-10-29

Germany

  • Eto-CellStadapharm Gmbh · 1 register entry
  • Eto-Cell®Stadapharm Gmbh · 1 register entry
  • Eto-GryTeva Gmbh · 1 register entry
  • EtopophosCheplapharm Arzneimittel Gmbh · 1 register entry
  • Etoposid AccordAccord Healthcare B.V. · 1 register entry
  • Etoposid HexalHexal Ag · 1 register entry
  • Etoposid HikmaHikma Farmacêutica (Portugal), S.A. · 1 register entry
  • RiboposidHikma Farmacêutica (Portugal), S.A. · 1 register entry
  • Vepesid KCheplapharm Arzneimittel Gmbh · 1 register entry

Source: EMA – Article 57 product data (EU/EEA), as of 2026-10-29

Turkey

  • EtopexDEVA HOLDİNG A.Ş. · 1 register entry
  • Etoposid EbeweSANDOZ İLAÇ SAN. VE TİC. A.Ş. · 2 register entries
  • EtosidKOÇAK FARMA İLAÇ VE KİMYA SAN. A.Ş. · 2 register entries
  • LastetONKO İLAÇ SAN. VE TİC. A.Ş. · 4 register entries
  • OncopozidVEM İLAÇ SAN. VE TİC. A.Ş. · 1 register entry

Source: TİTCK – Ruhsatlı Beşeri Tıbbi Ürünler Listesi, as of 2026-10-16

USA

  • EtopophosH2-Pharma, LLC · 1 register entry

Source: U.S. FDA – Drug labels (openFDA/DailyMed), as of 2026-10-29

Brand names in 26 more European countries
Belgium
Celltop, Eposin, Etoposide Accord Healthcare, Etoposide Fresenius Kabi, Vepesid
Bulgaria
Eтопозид Акорд
Croatia
Etoposide Sandoz
Cyprus
Etoposide Accord
Czechia
Etoposid Ebewe, Etoposide Accord, Etoposide Teva
Denmark
Etoposid Accord, Etoposid Ebewe, Etoposid Fresenius Kabi
Estonia
Etoposide Accord, Etoposide Kabi, Vepesid
Finland
Etoposid Fresenius Kabi, Etoposide Accord, Vepesid
France
Celltop, Etopophos, Etoposide Accord, Etoposide Hikma, Etoposide Teva, Etoposide Viatris
Greece
Etobion
Hungary
Etoposid Sandoz, Etoposide Accord, Etoposide Kabi, Etoposide Teva
Iceland
Etópósíð Accord
Ireland
Etoposide, Vepesid
Italy
Etoposide Accord, Etoposide Hikma, Etoposide Sandoz, Etoposide Teva, Vepesid
Latvia
Etoposide Accord, Etoposide Ebewe, Etoposide Kabi
Lithuania
Etoposid Ebewe, Etoposide Accord, Etoposide Kabi
Luxembourg
Eposin, Etoposide Accord Healthcare, Vepesid
Netherlands
Eposin, Etoposide Accord, Etoposide Fresenius Kabi, Etoposide Hikma, Toposin, Vepesid
Norway
Etoposid Ebewe, Etoposid Fresenius Kabi, Etoposide Accord, Vepesid
Poland
Etoposid Ebewe, Etopozyd Accord
Portugal
Etoposido Accord, Etoposido Hikma, Etoposido Sandoz
Romania
Etoposid Accord, Etoposide Teva, Etopozida Kabi, Vepesid
Slovakia
Etoposid Sandoz, Etopozid Accord
Slovenia
Ebeposid, Eposin, Etopozid Accord
Spain
Etopósido Accord, Etopósido Hikma, Etopósido Sandoz, Etopósido Teva, Vepesid
Sweden
Eposin, Etopofos, Etoposid Ebewe, Etoposid Fresenius Kabi, Etoposide Accord, Vepesid

EMA – Article 57 product data (EU/EEA), 2026-10-29

Medelix receives no money from pharmaceutical companies. Brand names are listed alphabetically and without ranking.

Another question about this substance?

Medelix answers clinical questions from guidelines, studies and product information – every claim with its source.

Sources

  1. U.S. Food and Drug Administration. Etoposide (Mylan Pharmaceuticals Inc.) – Prescribing Information, 2016-04-19. DailyMed (NLM), 2026-10-29. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=508a418e-985f-4208-9324-2230655bb5c2
  2. EMA – Article 57 product data (EU/EEA), 2026-10-29. https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/data-medicines-iso-idmp-standards-post-authorisation/public-data-article-57-database
  3. EMA – Article 57 product data (EU/EEA), 2026-10-29. https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/data-medicines-iso-idmp-standards-post-authorisation/public-data-article-57-database
  4. TİTCK – Ruhsatlı Beşeri Tıbbi Ürünler Listesi, 2026-10-16. https://www.titck.gov.tr/dinamikmodul/85
  5. U.S. FDA – Drug labels (openFDA/DailyMed), 2026-10-29. https://dailymed.nlm.nih.gov/dailymed/

Editorial: Medelix editorial team · last updated 2026-10-29 · How these pages are made · Report an error

Source: U.S. Food and Drug Administration (FDA), prescribing information, via DailyMed (NLM); public domain. Not advertising, not a treatment recommendation. For questions about your own treatment, ask your doctor or pharmacist.